Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)
NCT ID: NCT04363866
Last Updated: 2020-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2020-08-31
2021-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will receive their study intervention for 5 days, after which they will be considered off protocol- directed therapy and receive medical management of their disease according to institutional standards. Participants may be followed for up to 180 days from initiating protocol therapy for clinical outcome, after which they will discontinue study participation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hydroxychloroquine
400 mg bid (PO) Day 1, followed by 200 mg bid (PO) Day 2 through Day 5
Hydroxychloroquine
Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
Placebo
Placebo pill bid (PO) Day 1 through Day 5 of the treatment period
Placebo
A placebo is a pill that looks like the study drug but has no real medicine in it.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hydroxychloroquine
Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
Placebo
A placebo is a pill that looks like the study drug but has no real medicine in it.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Individuals aged ≥ 18 years of all races and ethnic groups.
3. Must have documented positive test result for SARS-CoV-2 (COVID19), or high clinical suspicion for SARS-CoV-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest X-ray or CT scan), lack of alternative diagnosis, and history of exposure to a known case of SARS-CoV- 2 infection within the past 14 days
4. Not receiving institutional therapy for treatment of SARS-CoV-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s).
5. Must meet at least one of the following clinical stratifications:
1. Have at least 1 minor criterion per ATS criteria (refer to Appendix A), or
2. Have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., X-ray or computed tomography \[CT\]), or
3. High risk for poor outcome, as defined by any one of the following:
i. Age ≥ 60 years old ii. Underlying medical comorbidities, defined as:
* Serious cardiovascular disease
* Poorly controlled diabetes (i.e., A1c levels \>7%)
* Chronic kidney disease requiring dialysis
* Significant liver disease (Pugh-Child B or C)
* Severe obesity (body mass index \[BMI\] ≥ 40)
* Chronic respiratory disease (e.g., COPD)
* Hypertension, defined as blood pressure ≥ 140 / 90 mmHg iii. Solid organ or stem cell transplant recipient iv. Diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy v. Receipt of biologic agent or prednisone \> 0.5 mg/kg/day (or equivalent)
6. Patient must be within 5 days of symptom onset, as determined by clinical team.
7. Participants with preexisting auditory damage are allowed.
8. Participants with a history of epilepsy are allowed.
9. Female participants of childbearing potential (FOCBP) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug.
10. FOCBP must agree to use highly-effective method(s) of contraception (Appendix B) during the study and for 1 months after the last dose of study drug. FOCBP are those who have not been surgically sterilized or have not been free from menses for \>1 year without an alternative medical cause.
11. Male participants must agree to use an adequate method of contraception (Appendix B) starting with the first dose of study therapy through at least 1 months after the last dose of study drug.
12. Participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.
Exclusion Criteria
2. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
3. Psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent.
4. Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation \>500 ms, electrolyte disturbances, etc.), or participants with congenital long QT syndrome
5. Patients with Myesthenia Gravis or other neuromuscular disorders
6. Patients with history of psoriasis.
a. May be waived at the discretion of the PI
7. Patients with history of porphyria
a. May be waived at the discretion of the PI
8. Concomitant use of other antiviral agents for the study's duration, but may be waived at discretion of the Principal Investigator
9. Hypersensitivity to the study agent, or any of its excipients.
10. Females who are pregnant or lactating.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OHSU Knight Cancer Institute
OTHER
Oregon Health and Science University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marcel Curlin
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marcel Curlin, MD
Role: PRINCIPAL_INVESTIGATOR
Oregon Health and Science University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oregon Health and Science University
Portland, Oregon, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00021303
Identifier Type: -
Identifier Source: org_study_id